Wells Fargo’s BriaCell Therapeutics BCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTX
Wells Fargo's BCTX Position: Q3 2026 in Review
Wells Fargo held its BriaCell Therapeutics (BCTX) position steady in Q3 2026 at 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #7214.
Wells Fargo first reported a position in BCTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $360 in Q3 2024. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2026.
- Wells Fargo held 1 share of BriaCell Therapeutics worth $4 as of Q3 2026.
- Wells Fargo left its BriaCell Therapeutics share count unchanged in Q3 2026.
- BriaCell Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #7214 holding.
- Wells Fargo first reported a position in BriaCell Therapeutics in Q3 2024 and has held it in 9 quarters since.
- Wells Fargo's BriaCell Therapeutics position peaked at $360 in Q3 2024.
- 19 funds tracked by Wall St. Rank held BriaCell Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.